Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
· · NYSE
$648.43
▲ $7.04 (+1.1%)
Market data updated: 09/17 01:29 PM
Fundamentals updated: 09/16/2026
News analyzed: 09/17/2026
Market Cap
$239.76B
Day Range
$638.00 - $653.40
52-Week Range
$435.27 - $653.40
Beta
—
Next Earnings
20.10.2026
+33.5% (1Y)
Strengths: 12/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 1.89
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: $159.64 vs. price $648.43 (-75.4%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
62
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
50
Quality
42
Value
33
Momentum
79
Risk
48
Sentiment
100
Fundamental
66
Institutional
0
Stocks with a similar DNA right now
SCANNING TMO...
Recent media coverage of Thermo Fisher Scientific highlights its expanding market presence and growth projections across key sectors. Reports emphasize its leadership in **veterinary diagnostics**, **blood-based biomarkers** (including Alzheimer’s testing), and **multiomics technologies**, particularly spatial omics. Market analyses also underscore its competitive positioning in **recombinant proteins**, **in vitro diagnostics (IVD) raw materials**, and broader industry trends like sustainability (e.g., My Green Lab’s EU compliance efforts). Technical analyses note strong investor sentiment, though no major operational or financial surprises are detailed.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Thermo Fisher Scientific Inc.. News trend score: 100. Reason: 12 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
45
🎯 Conviction (vs. Emotion)
36
Psychology
79
Fundamentals
66
Technical
79
Valuation
33
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+38%
Market Narrative
80
Fundamental Reality
36
Narrative Gap
+44
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a dominant *herding* dynamic, where investors align with peers despite modest underperformance. Euphoria and overconfidence persist due to extreme valuation disconnects from fundamentals, while FOMO and panic remain muted by neutral technical signals. The key question is whether the narrative gap (72 vs. 36) will sustain momentum or force a re-evaluation of overvaluation. The stock’s alignment with peers may break if sentiment shifts or fundamentals diverge further.
Updated: 09/09/2026, 09:24 AM
What could change this?
👥 What the crowd believes
"‘Veterinary Diagnostics industry is on a strong growth path’ (article 9)"
"‘See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030’ (article 8)"
"‘Blood Based Biomarkers Market Report’ and ‘FDA-Cleared Alzheimer’s blood test’ (article 3)"
"‘Thermo Fisher Scientific (TMO) shows a strong technical breakout setup’ (article 10)"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 55/100
🔴 Weakest match
Samuel Armstrong Nelson — 4/100
🗣️ Why do they disagree?
The debate reflects how each historic framework emphasizes different signals: Nelson’s cycle‑position score of 67 suggests the stock sits near an oversold zone, while the efficient‑market view of Malkiel & Bogle at 57 flags only a mixed case versus a broad index. Liquidity and risk‑focused lenses from Bagehot (55) and Loeb (53) see the stock as adequate but not exceptional, whereas Livermore’s neutral 50 score highlights an absence of a clear trend. Value‑oriented approaches such as Graham’s defensive (16) and enterprising (31) scores, Fisher’s growth quality (21), and Lynch’s growth‑at‑reasonable‑price bar (19) all signal that the stock fails key safety or quality criteria. In contrast, cycle‑aware investors like Howard Marks (49‑31 range) and crowd‑sentiment analysts such as Mackay (47) see middling or emerging excitement, leading to a more cautious but not outright negative assessment.
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 63
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 55
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 53
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 49
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 42
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 38
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 34
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 32
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 28
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 21
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 19
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 16
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 4
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 278 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
17.4%
Net Margin
15.0%
EBITDA Margin
17.4%
ROE
12.6%
ROA
6.1%
ROIC
—
EPS
$17.77
Cash
$9.85B
Total Debt
$42.70B
Current Ratio
1.89
Debt/Equity
0.80
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 15.6.2026 | $0.470 |
| 14.6.2026 | $0.470 |
| 13.3.2026 | $0.470 |
| 12.3.2026 | $0.470 |
| 15.12.2025 | $0.430 |
| 14.12.2025 | $0.430 |
| 15.9.2025 | $0.430 |
| 14.9.2025 | $0.430 |
| 13.6.2025 | $0.430 |
| 12.6.2025 | $0.430 |
| 14.3.2025 | $0.430 |
| 13.3.2025 | $0.430 |
How is Fair Value calculated? →
Current Price
$648.43
Estimated Fair Value (DCF)
$159.64
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-75.4%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-0.2%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -0.2% | $6.28B | $5.76B |
| 2 | 0.5% | $6.31B | $5.31B |
| 3 | 1.1% | $6.38B | $4.93B |
| 4 | 1.8% | $6.50B | $4.60B |
| 5 | 2.5% | $6.66B | $4.33B |
Base FCF (last actual year)
$6.29B
Terminal Value
$105.03B
Present Value of Terminal Value
$68.26B
Enterprise Value
$93.20B
Net Debt
$32.85B
Equity Value
$60.34B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$141.29
Tangible Book Value per Share (Tangible NAV)
-$31.20
Sentiment based on basic keywords (not AI) — 12 positive, 8 neutral, 0 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 16.9.2026
ChartMill · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 15.9.2026
PR Newswire · 15.9.2026
Yahoo · 15.9.2026
GlobeNewswire · 15.9.2026
SeekingAlpha · 15.9.2026
CNBC · 15.9.2026
Benzinga · 15.9.2026
GlobeNewswire · 15.9.2026
Yahoo · 15.9.2026
GlobeNewswire · 15.9.2026
Yahoo · 15.9.2026
GlobeNewswire · 14.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 11.9.2026
Thermo Fisher Scientific Inc. (TMO) currently has a StockIQ AI score of 62/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TMO currently scores 62/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, TMO's estimated fair value is $159.64, which is 75.4% below the current price of $648.43. This is one valuation model among several signals in the fair-value category, not a price target.
TMO's technical score is 79/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 1.89; Price is above the 50-day average; Price is above the 200-day average.
Based on the real signals StockIQ computed: Estimated fair value: $159.64 vs. price $648.43 (-75.4%); Operating margin is eroding over time; Calmar: 0.22 (3y annualized return 8.1% / max drawdown 37.5%).
Yes — TMO has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Pettiti Gianluca | Open Market Sale | 31.8.2026 | 400 | -400 | $614.38 |
| Pettiti Gianluca | Exercise of Derivative Securities | 31.8.2026 | 3,733 | +3,733 | $309.63 |
| Pettiti Gianluca | Exercise of Derivative Securities | 31.8.2026 | 3,733 | -3,733 | — |
| Pettiti Gianluca | Open Market Sale | 31.8.2026 | 3,733 | -3,733 | $614.38 |
| Shafer Michael D | Tax Withholding in Shares | 28.8.2026 | 227.245 | -227.245 | $622.18 |
| Shropshire Thomas B Jr. | Tax Withholding in Shares | 28.8.2026 | 49.024 | -49.024 | $622.18 |
| CASPER MARC N | Tax Withholding in Shares | 28.8.2026 | 724.766 | -724.766 | $622.18 |
| Shafer Michael D | Tax Withholding in Shares | 28.8.2026 | 210.806 | -210.806 | $622.18 |
| CASPER MARC N | Tax Withholding in Shares | 28.8.2026 | 531.851 | -531.851 | $622.18 |
| Meyer James | Tax Withholding in Shares | 28.8.2026 | 113.623 | -113.623 | $622.18 |
| Meyer James | Tax Withholding in Shares | 28.8.2026 | 19.824 | -19.824 | $622.18 |
| Shafer Michael D | Tax Withholding in Shares | 28.8.2026 | 189.533 | -189.533 | $622.18 |
| Meyer James | Tax Withholding in Shares | 28.8.2026 | 37.23 | -37.23 | $622.18 |
| Meyer James | Tax Withholding in Shares | 28.8.2026 | 44.483 | -44.483 | $622.18 |
| Shafer Michael D | Tax Withholding in Shares | 28.8.2026 | 162.457 | -162.457 | $622.18 |
| Pettiti Gianluca | Tax Withholding in Shares | 28.8.2026 | 303.639 | -303.639 | $622.18 |
| Pettiti Gianluca | Tax Withholding in Shares | 28.8.2026 | 269.794 | -269.794 | $622.18 |
| Britt Lisa P. | Tax Withholding in Shares | 28.8.2026 | 105.403 | -105.403 | $622.18 |
| Holmes Joseph R. | Tax Withholding in Shares | 28.8.2026 | 14.97 | -14.97 | $622.18 |
| Meyer James | Tax Withholding in Shares | 28.8.2026 | 55.12 | -55.12 | $622.18 |
| Britt Lisa P. | Tax Withholding in Shares | 28.8.2026 | 116.04 | -116.04 | $622.18 |
| Britt Lisa P. | Tax Withholding in Shares | 28.8.2026 | 87.03 | -87.03 | $622.18 |
| Pettiti Gianluca | Tax Withholding in Shares | 28.8.2026 | 249.003 | -249.003 | $622.18 |
| Holmes Joseph R. | Tax Withholding in Shares | 28.8.2026 | 10.567 | -10.567 | $622.18 |
| Holmes Joseph R. | Tax Withholding in Shares | 28.8.2026 | 12.915 | -12.915 | $622.18 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,690,588 shares short as of 2026-08-31 · vs. 4,985,877 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.5% of trading volume this week was short selling, vs. 46.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology